Table 1 NSABP FB-7: patient characteristics by randomized arm
Arm 1, n = 42 | Arm 2, n = 42 | Arm 3, n = 42 | |
|---|---|---|---|
Age, years | |||
Median | 50.0 | 56.0 | 50.0 |
Range | 33–71 | 29–71 | 31–77 |
Performance status | |||
ECOG 0 | 42 (100%) | 42 (100%) | 41 (97.6%) |
ECOG 1 | 0 | 0 | 1 (2.4%) |
Tumor stage | |||
IIB | 18 (42.8%) | 19 (45.2%) | 20 (47.6%) |
III | 21 (50%) | 20 (47.6%) | 22 (52.3%) |
Missing | 3 (7.1%) | 3 (7.1%) | 0 |
Inflammatory | 4(9.5%) | 7(16.7%) | 4(9.5%) |
Menopausal status | |||
Pre | 25 (60%) | 16 (38%) | 23 (55%) |
Post | 17 (40%) | 26 (62%) | 19 (45%) |
Hormone receptor | |||
Positive | 28 (67%) | 29 (69%) | 23 (55%) |
Negative | 14 (33%) | 13 (31%) | 19 (45%) |
Clinical tumor size | |||
Mean, cm | 4.50 | 5.04 | 4.72 |
Median, cm | 3.70 | 5.50 | 5.00 |
Range, cm | 0.0–18.0 | 0.0–10.0 | 0.0–9.0 |
HER2 | |||
IHC | 24 (57.1%) | 24 (57.1%) | 25 (59.5%) |
ISH | 15 (35.7%) | 12 (28.6%) | 11 (26.2%) |
IHC and ISH | 3 (7.1%) | 6 (14.3%) | 6 (14.3%) |